PacBio
About PacBio
At PacBio, our mission is to enable the promise of genomics to better human health.
Stock Symbol:
PACB
Stock Exchange:
NASDAQ
Introducing a whole new PacBio
216 articles with PacBio
-
PacBio to Participate in the BofA Securities 2022 Healthcare Conference
5/5/2022
PacBio announced that it will be participating in the upcoming BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada.
-
PacBio Announces First Quarter 2022 Financial Results
5/4/2022
PacBio announced financial results for the quarter ended March 31, 2022.
-
PacBio transforms access to the epigenome and streamlines workflows
4/21/2022
PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced the release of a transformative capability to detect DNA methylation using the Sequel IIe and Sequel II Systems.
-
PacBio and Children’s Mercy Kansas City Expand Collaboration Taking a Multi-Omics Approach to Characterize Rare Disease
4/21/2022
PacBio announced an expanded research collaboration with Children’s Mercy Kansas City, one of the nation’s top pediatric medical systems, to use the multi-omics capabilities of PacBio’s Sequel IIe system in the study of genetic disease.
-
PacBio to Report First Quarter 2022 Financial Results on May 4, 2022
4/20/2022
PacBio announced that it will hold its quarterly conference call to discuss its first quarter 2022 financial results on Wednesday, May 4, 2022, at 5:00 pm Eastern Time.
-
Scientists recently announced the complete sequencing of the entire human genome. Biotech company PacBio - and HiFi sequencing - played a big role in this milestone.
-
PacBio Enters Agricultural Industry Collaboration with Corteva Agriscience to Develop High-Throughput Plant, Pest and Microbial Sequencing
4/4/2022
PacBio, a leading provider of high-quality, highly accurate sequencing platforms, announced a new collaboration with global agriculture company, Corteva Agriscience, to develop custom, end-to-end workflows for plant, pest and microbial sequencing.
-
HiFi Reads Enable Telomere-to-Telomere Consortium to Fill the Final Gaps in the Human Genome, Heralding a New Era of Research into Genetic Diseases and Human Biology
3/31/2022
PacBio, a leading provider of high-quality, highly accurate sequencing solutions, announced PacBio’s essential contribution to the completion of the first truly complete human reference genome.
-
PacBio Opens European Headquarters in London
3/23/2022
PacBio, a leading developer of high-quality, highly accurate, sequencing platforms, announced the company’s expansion to better serve customers in the Europe, Middle East and Africa region.
-
PacBio Grants Equity Incentive Award to New Employee - Feb 25, 2022
2/25/2022
PacBio announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of PacBio common stock, and restricted stock units covering 50,000 shares of PacBio common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan effective on February 22, 2022.
-
KK Women’s and Children’s Hospital and PacBio Collaborate in Asia’s First Study of Unexplained Neurodevelopmental Disorders
2/16/2022
KK Women’s and Children’s Hospital and PacBio, a leading provider of high-quality, highly accurate sequencing platforms, announced a collaboration to leverage PacBio technology in understanding the genetic causes of neurodevelopmental disorders.
-
PacBio Announces Fourth Quarter and Fiscal Year 2021 Financial Results
2/15/2022
PacBio announced financial results for the quarter and fiscal year ended December 31, 2021.
-
Pacific Biosciences of California, Inc. Third Quarter 2021 Financial Results Call
10/19/2021
Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its third quarter 2021 financial results on Tuesday, November 2, 2021, at 4:30pm Eastern Time.
-
Pacific Biosciences Grants Equity Incentive Award to New Employee - Sep 24, 2021
9/24/2021
Pacific Biosciences of California, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of Pacific Biosciences common stock, and restricted stock units covering 50,000 shares of Pacific Biosciences common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan effective on September 20, 2021.
-
Pacific Biosciences Closes Acquisition of Omniome and Establishes San Diego Presence
9/20/2021
Pacific Biosciences of California, Inc. announced today the companies have closed the transaction under which Pacific Biosciences acquired Omniome.
-
Pacific Biosciences of California, Inc. to Present at Upcoming Investor Conferences - Sep 03, 2021
9/3/2021
Pacific Biosciences of California, Inc. announced that its executives will be speaking at the following investor conferences.
-
Pacific Biosciences of California, Inc. to Present at Upcoming Investor Conference - Aug 09, 2021
8/9/2021
Pacific Biosciences of California, Inc. announced that its executives will be speaking at the following investor conference:.
-
Pacific Biosciences of California, Inc. Announces Second Quarter 2021 Financial Results
8/3/2021
Pacific Biosciences of California, Inc. announced financial results for the quarter ended June 30, 2021.
-
Pacific Biosciences Signs Definitive Agreement to Acquire Omniome
7/20/2021
Pacific Biosciences of California, Inc., a leading provider of high-quality, long-read sequencing platforms, announced that it has signed a definitive merger agreement under which it will acquire Omniome, a San Diego-based company developing a highly differentiated, proprietary short-read sequencing platform capable of delivering high accuracy.
-
Pacific Biosciences and Invitae Announce Intent to Expand Collaboration
7/20/2021
Pacific Biosciences of California, Inc., a leading provider of high-quality, long-read sequencing platforms, and Invitae Corporation, a leading medical genetics company, announced an intent to expand their multi-year collaboration to develop a production-scale high-throughput HiFi sequencing platform to include the sequencing technology developed by Omniome, Inc.